Alphabet’s Calico Life Sciences has entered a licensing agreement with China-based Mabwell Bioscience valued up to $571 million, acquiring rights to a clinical-stage monoclonal antibody targeting interleukin-11. This investigational treatment aims at age-related diseases, including idiopathic pulmonary fibrosis, with ongoing phase 1 trials in China and Australia. Calico retains exclusive development and commercialization rights globally except in greater China. The agreement aligns with Calico’s mission to understand aging biology and deliver novel therapeutics for longevity, bolstering its pipeline with innovative candidates.